Match!
Kris V. Kowdley
Virginia Mason Medical Center
VirologyDiabetes mellitusGeneral surgeryMedicineGastroenterology
621Publications
76H-index
25.5kCitations
What is this?
Publications 630
Newest
#1Kris V. KowdleyH-Index: 76
#2Raj Vuppalanchi (IU: Indiana University)H-Index: 30
Last. Simon M. Rushbrook (UEA: University of East Anglia)H-Index: 18
view all 17 authors...
Abstract Background & Aims Primary sclerosing cholangitis (PSC) is a rare, cholestatic liver disease with no currently approved therapies. Obeticholic acid (OCA) is a potent farnesoid X receptor (FXR) agonist approved for the treatment of primary biliary cholangitis. We investigated the efficacy and safety of OCA in patients with PSC. Methods AESOP was a phase II, randomized, double-blind, placebo-controlled, dose-finding study. Eligible patients were 18 to 75 years of age with a diagnosis of PS...
Source
Source
Summary Up to 40% of patients with primary biliary cholangitis have an incomplete response to first-line treatment with ursodeoxycholic acid. Obeticholic acid was approved by the US Food and Drug Administration in 2016 as a second-line treatment for patients with primary biliary cholangitis who are unresponsive to ursodeoxycholic acid; however, approximately 50% of patients might need additional treatments to reach therapeutic goals. A considerable need exists for effective treatment options to ...
Source
#2Jorn C Goet (Erasmus University Medical Center)H-Index: 3
Last. George N. DalekosH-Index: 34
view all 25 authors...
Background & Aims Patients usually receive a diagnosis of primary biliary cholangitis (PBC) at an early stage, based on biochemical analyses. We investigated the proportion of patients who progress to moderate or advanced PBC and factors associated with progression and patient survival. Methods We obtained data from 1615 patients (mean age, 55.4 y) with early stage PBC (based on their normal levels of albumin and bilirubin), collected at the time of initial evaluation or treatment, from the Glob...
Source
Source
#1Michael Trauner (Medical University of Vienna)H-Index: 76
#2Yevgeniy GindinH-Index: 1
Last. Christopher L. Bowlus (UC Davis: University of California, Davis)H-Index: 41
view all 13 authors...
Abstract Background A DNA methylation (DNAm) signature derived from 353 CpG sites (the Horvath clock) has been proposed as an epigenetic measure of chronological and biological age. This epigenetic signature is accelerated in diverse tissue types in various disorders, including nonalcoholic steatohepatitis, and is associated with mortality. Here, we assayed whole blood DNAm to explore age acceleration in patients with PSC. Methods Using the MethylationEPIC BeadChip (850K) array, DNAm signatures ...
1 CitationsSource
#1Rohit Loomba (UCSD: University of California, San Diego)H-Index: 58
#2Brent A. Neuschwander-Tetri (SLU: Saint Louis University)H-Index: 42
Last. Cynthia Behling (UCSD: University of California, San Diego)H-Index: 33
view all 15 authors...
Source
#1Vlad Ratziu (University of Paris)H-Index: 49
#2Arun J. Sanyal (VCU: Virginia Commonwealth University)H-Index: 102
Last. Frank Tacke (Charité)H-Index: 3
view all 13 authors...
1 CitationsSource
#1Maren H. Harms (Erasmus University Medical Center)H-Index: 5
#2Rozanne C de Veer (Erasmus University Medical Center)
Last. Adriaan J. van der Meer (Erasmus University Medical Center)H-Index: 17
view all 21 authors...
Objective The clinical benefit of ursodeoxycholic acid (UDCA) in primary biliary cholangitis (PBC) has never been reported in absolute measures. The aim of this study was to assess the number needed to treat (NNT) with UDCA to prevent liver transplantation (LT) or death among patients with PBC. Methods The NNT was calculated based on the untreated LT-free survival and HR of UDCA with respect to LT or death as derived from inverse probability of treatment weighting-adjusted Cox proportional hazar...
Source
#1Zobair M. Younossi (Inova Health System)H-Index: 84
#2Vlad Ratziu (University of Paris)H-Index: 49
Last. Massimo ZuinH-Index: 1
view all 351 authors...
Summary Background Non-alcoholic steatohepatitis (NASH) is a common type of chronic liver disease that can lead to cirrhosis. Obeticholic acid, a farnesoid X receptor agonist, has been shown to improve the histological features of NASH. Here we report results from a planned interim analysis of an ongoing, phase 3 study of obeticholic acid for NASH. Methods In this multicentre, randomised, double-blind, placebo-controlled study, adult patients with definite NASH, non-alcoholic fatty liver disease...
12 CitationsSource
12345678910